These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23226334)

  • 1. [18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice.
    Munk Jensen M; Erichsen KD; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
    PLoS One; 2012; 7(11):e50618. PubMed ID: 23226334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.
    Jensen MM; Erichsen KD; Björkling F; Madsen J; Jensen PB; Højgaard L; Sehested M; Kjær A
    PLoS One; 2010 Sep; 5(9):e12965. PubMed ID: 20885974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.
    Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Bzorek M; Jensen PB; Højgaard L; Sehested M; Kjær A
    PLoS One; 2013; 8(1):e53410. PubMed ID: 23308217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.
    Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
    BMC Cancer; 2013 Apr; 13():168. PubMed ID: 23548101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
    Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
    Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.
    Lee SJ; Kang HY; Kim SY; Chung JH; Oh SJ; Ryu JS; Kim SB; Kang JS; Park SK; Kim HM; Kim MH; Moon DH
    Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1436-48. PubMed ID: 21484374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in mice.
    Johnbeck CB; Munk Jensen M; Haagen Nielsen C; Fisker Hag AM; Knigge U; Kjaer A
    PLoS One; 2014; 9(3):e91387. PubMed ID: 24626055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901.
    Leyton J; Smith G; Lees M; Perumal M; Nguyen QD; Aigbirhio FI; Golovko O; He Q; Workman P; Aboagye EO
    Mol Cancer Ther; 2008 Sep; 7(9):3112-21. PubMed ID: 18790789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET.
    Munk Jensen M; Erichsen KD; Björkling F; Madsen J; Jensen PB; Sehested M; Højgaard L; Kjær A
    PLoS One; 2013; 8(12):e85126. PubMed ID: 24386456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
    Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
    Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.
    Cawthorne C; Burrows N; Gieling RG; Morrow CJ; Forster D; Gregory J; Radigois M; Smigova A; Babur M; Simpson K; Hodgkinson C; Brown G; McMahon A; Dive C; Hiscock D; Wilson I; Williams KJ
    Mol Cancer Ther; 2013 May; 12(5):819-28. PubMed ID: 23427298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.
    Wang H; Zhang J; Tian J; Qu B; Li T; Chen Y; Liu J; Wang S
    J Nucl Med; 2009 Nov; 50(11):1857-64. PubMed ID: 19837754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer.
    Schelhaas S; Held A; Wachsmuth L; Hermann S; Honess DJ; Heinzmann K; Smith DM; Griffiths JR; Faber C; Jacobs AH
    Cancer Res; 2016 Dec; 76(24):7096-7105. PubMed ID: 27784748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.
    Perumal M; Stronach EA; Gabra H; Aboagye EO
    Mol Imaging Biol; 2012 Dec; 14(6):753-61. PubMed ID: 22484552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
    McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC
    J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging.
    Schelhaas S; Wachsmuth L; Viel T; Honess DJ; Heinzmann K; Smith DM; Hermann S; Wagner S; Kuhlmann MT; Müller-Tidow C; Kopka K; Schober O; Schäfers M; Schneider R; Aboagye EO; Griffiths J; Faber C; Jacobs AH
    J Nucl Med; 2014 Jun; 55(6):983-8. PubMed ID: 24777288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
    Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
    Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
    Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
    Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.